Celularity Inc (CELU)

↓ Download CSV

CIK 0001752828 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Celularity Inc reported revenue of $26.55M, down 51.0% from the prior year. The company ran a net loss, with a net margin of -345.4%. It held $107.33M in total assets against $145.39M in total liabilities.

Key ratios (FY2025)

-230.9%
Operating margin
-345.4%
Net margin
-51.0%
Revenue growth (YoY)
Metric (FY)20252024202320222021202020192018
Revenue$26.55M$54.22M$22.77M$17.98M$21.34M$14.28M
Cost of Revenue$20.07M$14.99M$16.02M
Gross Profit$6.75M-$1.69M$11.68M$9.35M
Operating Income-$61.31M-$38.36M-$192.29M-$25.60M-$109.06M-$151.93M-$1.68M
Net Income-$91.72M-$57.89M-$196.29M$14.19M-$100.12M-$208.23M$5.88M
EPS (Diluted)$-3.59$-2.64$-11.02$0.95$-1.49
Total Assets$107.33M$132.68M$143.89M$401.07M$414.13M$431.01M$291.61M$174.5K
Total Liabilities$145.39M$123.84M$102.93M$202.16M$314.71M$412.30M$28.21M$150.6K
Shareholders' Equity-$38.06M$8.84M$40.96M$198.90M$99.42M-$531.40M-$327.42M$23.9K
Cash & Equivalents$6.17M$738.0K$227.0K$13.97M$37.24M$54.31M$917.0K$24.7K
Operating Cash Flow-$13.25M-$6.40M-$38.69M-$137.88M-$110.10M-$63.19M-$1.10M
Capital Expenditures$161.0K$1.05M$5.24M$6.20M$27.83M
Shares Outstanding28.84M22.55M19.38M14.89M124.31M18.53M3.17M